News
Events
RSS Feeds

News VERITY NAMED A 'TOP ... | AUTONOMY TECHNOLOGY ... | VIRAGEâ„¢ ANNOUNCES VS...
Press Release
Related Events
Related Case Studies
Related Resources

Autonomy Technology Selected as part of AstraZeneca's Enterprise Wide Intelligent Information Framework

SAN FRANCISCO, Calif. - November 5, 2003 - Autonomy Corporation plc (Nasdaq: AUTN; LSE: AU., Nasdaq Europe: AUTN), a global leader in infrastructure software for the enterprise, today announced that AstraZeneca, a global pharmaceutical leader, has selected Autonomy's Intelligent Data Operating Layer (IDOL) as an enterprise wide standard to automate the retrieval, delivery and routing of content from a wide range of internal and external information sources. The new AstraZeneca service is also planned to replace a number of rules based legacy technologies, which are presently deployed within the company's global intranet.

AstraZeneca chose Autonomy's IDOL platform to supply an internal intelligent information service for all users working across multiple internal applications, information sources, as well as content from numerous external news sources. Their decision follows an extensive strategic evaluation of available technologies. As a world leading company spending in excess of $11m per day on research and development, it is vital for AstraZeneca that its employees have access to the most up to date and precisely relevant information available.

Important to AstraZenca's decision was Autonomy's context based approach, which automatically recognizes unknown relationships within information and links those to operations a user is performing on the desktop. This highlights potentially valuable R&D opportunities that can be exploited, that could not be discovered by a users reactive search routine and delivers significant return on investment. This ability to discover the ‘unknown' is explained by Senior Forrester Analyst Dan Rasmus who comments: "Unlike technologies that simply categorize content and then expose those categories to end users, the Autonomy engine builds complex, multiple variant models of existing content... The other model, using a rules-based or explicit knowledge approach, is too costly because rules must be written with the assumption that things are known. [Users] are looking not only for the known, but also for the unknown (new relationships) and rules cannot accommodate that."*

Carol Eastwood, VP of Quality and Information management who is sponsoring the enterprise search service for AstraZeneca says, "Autonomy is already widely used to support Product Knowledge Transfer across a larger global AstraZeneca community, this agreement will widen the reach and quality of searches to all communities and help maximize use and exploitation of all information assets across the business".

Mike Lynch, CEO and Founder of Autonomy today commented; "We are delighted to announce this new global agreement with AstraZeneca which cements our continuing working relationship. Autonomy is rapidly becoming the de facto standard for high level information management within pharmaceutical industry, with four out of the five leading pharmaceutical companies using Autonomy's technology to power information systems that provide their employees with better access to critical information. In addition, AstraZeneca has utilized Autonomy's unique ability to seamlessly integrate with other vendor's products, in this instance Vignette, who are an Autonomy OEM."

Autonomy's unique Intelligent Data Operating Layer (IDOL) integrates unstructured, semi-structured and structured information from multiple repositories through an understanding of their content. Autonomy grants enterprises the flexibility to use advanced information retrieval or legacy-based approaches. At the heart of Autonomy's software is its ability to process text, voice and video and identify and rank the main concepts within them. It then automatically categorizes, links, summarizes, personalizes and delivers that information. Autonomy's technology also drives collaboration across the enterprise and enables organizations to effectively leverage expertise. Autonomy's infrastructure technology is used to automate operations within enterprise information portals, customer relationship management, knowledge management, business intelligence and e-business applications, among others.

* 'Autonomy Connects With Homeland Security', Daniel W. Rasmus, October 22 2003.

About Autonomy

Autonomy Corporation plc (Nasdaq: AUTN; Nasdaq Europe: AUTN; LSE: AU.) is a global leader in infrastructure software for the enterprise. Autonomy's technology powers applications dependent upon unstructured information including call center, customer relationship management, knowledge management, enterprise portals, enterprise resource planning, online publishing and security applications. In addition to Autonomy's core infrastructure products, the Autonomy group of companies includes Aungate, a leading supplier of electronic communications management for regulatory compliance in the enterprise, Audentify, a leading supplier of next-generation contact center technology and Virage, a leading provider of rich media communication and content management software. Autonomy's customer base includes more than 1000 global companies including BAE Systems, Ford, Ericsson, Royal Sun Alliance, Sun Microsystems and public sector agencies including the U.S. Department of Defense, NASA and the US Department of Energy. Strategic reseller and OEM partners include leading companies such as ATG, BEA, Business Objects, Brio, Citrix, Computer Associates, EDS, IBM Global Services, iManage, Novell, Novient, Vignette and Sybase. The company has offices worldwide.

About AstraZeneca

AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services. It is one of the top five pharmaceutical companies in the world with healthcare sales of over $17.8 billion and leading positions in sales of gastrointestinal, oncology, cardiovascular, neuroscience and respiratory products. AstraZeneca is listed in the Dow Jones Sustainability Index (Global and European) as well as the FTSE4Good Index.

Caution Concerning Forward-Looking Statements

With the exception of historical information, the matters set forth in this news release are forward-looking statements that involve risks and uncertainties. A number of important factors could cause actual results to differ materially from those in the forward-looking statements. These factors include, among others, technology risks, including dependence on core technology; fluctuations in quarterly results; dependence on new product development; rapid technological and market change; reliance on sales by others; management of growth; dependence on key personnel; rapid expansion; growth of the Internet; financial risk management; and future growth subject to risks. These factors and other factors, which could cause actual results to differ materially are also discussed in the company's filings with the United States Securities and Exchange Commission, including Autonomy's Annual Report on Form 20-F and Registration Statements on Form F-1.

For more information, please contact:
Kris Marubio
Autonomy Corporation plc
+1 415/243-9955
krism@us.autonomy.com
Ian Black
Autonomy Corporation plc
+44 (0) 1223 448 000
ianb@autonomy.com
Carolyn Adams
Schwartz Communications, Inc.
415/512-0770
autonomy@schwartz-pr.com
Edward Bridges
Financial Dynamics
+44 207 831 3113
edward.bridges@fd.com

This is a selection of our forthcoming events, please visit our seminars page for more information.

Automatic Hyperlinks provided by IDOL Server 10

This is a small selection of the Autonomy case studies available, please visit our publications site at http://publications.autonomy.com/ for more information.

Automatic Hyperlinks provided by IDOL Server 10

Tweet this articletweet this
+1 415 243 9955

About Us
Technology
Functionality
Products
Solutions
Services
Customers
Partners
News & Events
Contact Us